Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by poneon Jun 09, 2015 10:04pm
57 Views
Post# 23813913

RE:RE:Why Ranbaxy?

RE:RE:Why Ranbaxy?
truthseeker2012 wrote: Ranbaxy had the technology for the slow release of the drug with the patent. Cipher had the formula for the drug. Ranbaxy were bought out by Sun Pharma late last year as Ranbaxy had lots of troubles throughout their entire organization.



Two technologies added together does not one marketing company make!   In other words, this strategy simply combined two technologies, but did not either build a marketing organization, or hand off marketing to a larger company.

Now I fear even if they did get a deal with a larger pharmaceutical to market it, they are going to dilute their profits by splitting with Ranbaxy.

Probably the CEO is right to do this deal that is going to diversify them.  No easy way to fix what is broken in the Ranbaxy deal.

The reason TEVA grows share is that they have a well oiled sales machine....
Bullboard Posts